Document Detail


Anticoagulation in atrial fibrillation: the trials and tribulations of keeping within therapeutic range.
MedLine Citation:
PMID:  18402716     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Atrial fibrillation (AF) is a growing epidemic in the developed world that has attracted much attention due to the associated risk of stroke and thromboembolism. This article discusses the application of oral anticoagulation (OAC) therapy with vitamin K antagonists (VKA) in order to reduce these risks. The article provides an overview of OAC management and highlights the need for greater efforts to increase time within therapeutic range.
Authors:
Jaspal S Taggar; Gregory Y H Lip
Related Documents :
7369096 - Low dose heparin in the prevention of deep-vein thromboses in patients with acute myoca...
3772836 - Type a behaviour in arab patients with myocardial infarction.
9779026 - Antithrombotic treatment of acute coronary syndromes.
12736096 - Transient global amnesia associated with an acute infarction in the retrosplenium of th...
24926306 - Aortic arch atherosclerosis in ischaemic stroke of unknown origin affects prognosis.
1729876 - Ischemic stroke and intracranial hemorrhage following thrombolytic therapy for acute my...
Publication Detail:
Type:  Editorial     Date:  2008-04-09
Journal Detail:
Title:  Current medical research and opinion     Volume:  24     ISSN:  1473-4877     ISO Abbreviation:  Curr Med Res Opin     Publication Date:  2008 May 
Date Detail:
Created Date:  2008-05-16     Completed Date:  2008-07-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  England    
Other Details:
Languages:  eng     Pagination:  1455-8     Citation Subset:  IM    
Affiliation:
University Department of Medicine, City Hospital, Birmingham, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Aged
Aged, 80 and over
Anticoagulants / administration & dosage*,  adverse effects
Atrial Fibrillation / complications,  drug therapy*,  mortality*
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Great Britain
Humans
Male
Maximum Tolerated Dose
Prognosis
Randomized Controlled Trials as Topic
Risk Assessment
Severity of Illness Index
Stroke / prevention & control*
Survival Analysis
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anticoagulants

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systema...
Next Document:  Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with...